DiaSys β-Hydroxybutyrate 21 FS represents a significant advancement in managing diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication of diabetes.

Due to the reduced availability of insulin and the resulting impaired glucose uptake, the body increasingly turns to the breakdown of fat as energy source. Free fatty acids are converted into ketone bodies, which can be used by various tissues. If ketone bodies exceed a certain level, they overwhelm the body’s buffering systems, leading to serious medical conditions.

Although urine strip tests are considered the gold standard in ketosis management, their ability to reliably assess DKA is limited.

They primarily detect acetoacetate, but not β-hydroxybutyrate (β-OHB), which accounts for 78% of the formed ketone bodies. Furthermore, results can be influenced by urine concentration and hydration status and can be influenced by certain medications or vitamin C intake.

β-Hydroxybutyrate21 FS enables fast and reliable quantitative determination for improved DKA management.